The agar-gel precipitin-inhibition technique has been modified to detect antibodies of Histoplasma capsulatum in sera from human clinical cases and experimental animals infected with this organism. By use of this modified technique, the histoplasmosis can be detected more consistently and reliably than with the direct agar-gel diffusion test, and titers are comparable to those attained by the complement-fixation serological technique.
supports an earlier report concerning the CF test by Campbell and Binkley (1) .
Unfortunately, neither the direct diffusion agar-gel nor the FA serological procedure can give titrations of sera comparable to those attained with the CF test. Moreover, CF titers of low magnitude (1:8 or 1:16) are negative by the FA and agar-gel techniques. This condition is similar to that observed by Ray and Kadull (6, 7) and Ray and Shay (8) in soluble antigen-antibody systems of anthrax, plague, and C-reactive protein, respectively, and has prompted investigation with the agar-gel precipitin-inhibition (AGPI) technique in this serological system.
MATERIALS AND METHODS
Preparation of agar-diffusion test plates and reading lamp. The medium test plates and agar diffusion reading lamp were prepared as described by Ray and Kadull (6) .
H. capsulatum test antigens. The antigen used in this proposed serological AGPI test was obtained from the Communicable Disease Center, Atlanta, Ga., as their histoplasmin (agar-gel) precipitin lots 2 and 3, catalog number 77-1002, which corresponds to the fivefold concentration of histoplasmin employed by Schubert, Lynch, and Ajello (9) .
H. capsulatum test antiserum. The test antiserum used routinely in the AGPI test was lots 13 and 22 human control histoplasmosis serum obtained from the Communicable Disease Center.
Box titration of the histoplasmosis antigen-antibody system. A box titration of the histoplasmosis antigen (lots 2 and 3) versus the histoplasmosis antiserum (lots 13 and 22) was performed in agar diffusion plates. Five serial twofold dilutions of the antigen (0.5 ml) and of the antiserum (0.2 ml) were prepared in physiological saline. To each dilution, an equivalent volume of physiological saline was added to give a final dilution range of 1:2 to 1:32.
The antigen dilutions were added sequentially and in duplicate to the two outer rows of wells (approximately 0.07-ml volume per well) so that one row exactly duplicated the Each of the wells in the center row of agar diffusion plates was filled with a MRD, of the positive histoplasmosis human control serum, and the plates were incubated at room temperature (23 to 27 C) for 1 hr. Conclusions of incubation periods for the plates and for the antigen-antibody binding mixture were timed to coincide and permit immediate completion of the final step.
Outer rows of wells were filled sequentially and in duplicate with the incubated antigen-serum dilution mixtures. Thus, each well in one outer row contained the same mixture as the corresponding well in the opposite outer row. The end point, or titer, of an unknown positive serum was the dilution that completely inhibited the formation of a visible line of precipitate with the box-titered MRDa and MRDS in the agar-gel plates (Fig. 1) .
Controls subjected to the same test procedure consisted of dilutions of the test antigen in saline and combinations of the predetermined MRDG of antigen with negative and positive histoplasmosis sera.
Agar-plate precipitin test for histoplasmosis. The direct diffusion agar-plate precipitin test for histoplasmosis described by Schubert, Lynch, and Ajello (9) was performed in the agar-gel plates previously described for use in the AGPI test. This allowed similar conditions of diffusion for the Histoplasma antigen and antibody comparative evaluation (Fig. 2) .
CF test for histoplasmosis. When the CF test was performed on serum specimens, the procedure used was that described by Smith et al. (11) . The overnight fixation procedure and 100l% fixation end point were employed in these CF determinations. The Histoplasma mycelial-and yeast-phase antigens and the positive human CF control serum were obtained from the Diagnostic Reagents Section, Communicable Disease Center, Atlanta, Ga., and were from lots 23, 31, and 22, respectively.
RESULTS
The AGPI test sensitivity was initially determined on serial sera from two human cases of histoplasmosis and a positive human CF control serum (Table 3 ). In addition, positive human CF (Fig. 2) . To obtain titers, it was necessary to perform a box titration of the antigen-antibody system. Serial dilutions of precipitin antigen (lot 2) were reacted in agar-gel plates with serial dilutions of human positive histoplasmosis CF control serum (lot 13). These dilutions were added to the agargel plates simultaneously, and incubated at room temperature for an observation period of 48 hr; additional incubation did not enhance the precipitin line formation. The results recorded at 48 hr are shown in Table 1 . Thus, the derivation of the MRD of each reactant was obtained and could be applied to the titration of the positive histoplasmosis human sera in the AGPI technique. It was noticed, however, that the line of precipitate was relatively close to the antiserum or antibody well. To obtain a reaction equidistant between these antigen and antibody wells, it was necessary to prediffuse the MRDg 1 hr prior to the addition of the unknown serum*-MRDa mixture in performing the test. Recently, three human sera obtained from M. Furcolow's laboratory through the courtesy of John Converse proved to be very interesting (serum numbers 1, 2, and 3, Table 4 ). These were aberrant sera in that sera 1 and 2 were not positive by the agar-plate method of Schubert et al. (9) nor by the FDSL CF techniques; however, serum 3 showed anticomplementary activity by the latter test. These sera, in addition to control sera from the previous experiment (Table 3, Figure 3 shows the precipitin reaction. It is significant that serum 7 ( Fig. 3) antigen of H. capsulatum. This same serum also reacted with serum 5 irrespective of the antigen wells, indicating the presence of antihuman serum antibodies in this serum.
